Transgene-mediated enkephalin expression attenuates signs of naloxone-precipitated morphine withdrawal in rats with neuropathic pain

Behavioural Brain Research

Volumn 197, Issue 1, 2009, Pages 84-89

  Hao, Shuanglin ^a   Hu, Jian ^a   Fink, David J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Enkephalin; Gene therapy; Herpes simplex; Morphine; Physical withdrawal

Indexed keywords

ENKEPHALIN; HERPESVIRUS VECTOR; MORPHINE; NALOXONE; PROENKEPHALIN;

ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIARRHEA; EMBRYO; GENE OVEREXPRESSION; JUMPING; LONG TERM CARE; LUMBAR SPINE; MALE; NEUROPATHIC PAIN; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTOSIS; RAT; SPINAL GANGLION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WEIGHT REDUCTION; WET DOG SHAKES; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; DISEASE MODELS, ANIMAL; ENKEPHALINS; GANGLIA, SPINAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; LIGATION; LUMBAR VERTEBRAE; MALE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; SIMPLEXVIRUS; SPINAL NERVE ROOTS; SUBSTANCE WITHDRAWAL SYNDROME; TRANSGENES;

EID: 57649203290     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.08.005     Document Type: Article

References (47)

1. Bell J.A., and Jaffe J.H. Electrophysiological evidence for a presynaptic mechanism of morphine withdrawal in the neonatal rat spinal cord. Brain Res 382 (1986) 299-304
2. Blasig J., Herz A., Reinhold K., and Zieglgansberger S. Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia 33 (1973) 19-38
3. Braz J., Beaufour C., Coutaux A., Epstein A.L., Cesselin F., Hamon M., et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 21 (2001) 7881-7888
4. Buccafusco J.J., and Marshall D.C. Dorsal root lesions block the expression of morphine withdrawal elicited from the rat spinal cord. Neurosci Lett 59 (1985) 319-324
5. Buccafusco J.J., Terry A.V., and Shuster J.L. Spinal NMDA receptor-nitric oxide mediation of the expression of morphine withdrawal symptoms in the rat. Brain Res 679 (1995) 189-199
6. Cami J., and Farre M. Drug addiction. N Engl J Med 349 (2003) 975-986
7. Cao J.L., He J.H., Ding H.L., and Zeng Y.M. Activation of the spinal ERK signaling pathway contributes naloxone-precipitated withdrawal in morphine-dependent rats. Pain 118 (2005) 336-349
8. Cao J.L., Liu H.L., Wang J.K., and Zeng Y.M. Cross talk between nitric oxide and ERK1/2 signaling pathway in the spinal cord mediates naloxone-precipitated withdrawal in morphine-dependent rats. Neuropharmacology 51 (2006) 315-326
9. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 (1994) 55-63
10. Christie M.J., Williams J.T., Osborne P.B., and Bellchambers C.E. Where is the locus in opioid withdrawal?. Trends Pharmacol Sci 18 (1997) 134-140
11. Delander G.E., and Takemori A.E. Spinal antagonism of tolerance and dependence induced by systemically administered morphine. Eur J Pharmacol 94 (1983) 35-42
12. Dixon W.J. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20 (1980) 441-462
13. Dzoljic M.R., Bokszanska A., Korenhof A.M., Kaplan C.D., Dzoljic M., Rupreht J., et al. The effects of orally active enkephalinase inhibitors on morphine withdrawal syndrome. Neuroreport 3 (1992) 637-640
14. Dzoljic M.R., Rademaker B., vd Poel-Heisterkamp A.L., Ukponmwan O.E., and Haffmans J. Enkephalinase inhibition suppresses naloxone-induced jumping in morphine-dependent mice. Arch Int Pharmacodyn Ther 283 (1986) 222-228
15. Gellert V.F., and Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 205 (1978) 536-546
16. Gmerek D.E., Katz J.L., France C.P., and Woods J.H. Systemic and intracerebroventricular effects of opioid peptides in withdrawn morphine-dependent rhesus monkeys. Life Sci 33 Suppl. 1 (1983) 361-364
17. Goss J.R., Mata M., Goins W.F., Wu H.H., Glorioso J.G., and Fink D.J. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther 8 (2001) 551-556
18. Gu G., Kondo I., Hua X.Y., and Yaksh T.L. Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence. J Pharmacol Exp Ther 314 (2005) 1362-1369
19. Gudehithlu K.P., Tejwani G.A., and Bhargava H.N. Beta-endorphin and methionine-enkephalin levels in discrete brain regions, spinal cord, pituitary gland and plasma of morphine tolerant-dependent and abstinent rats. Brain Res 553 (1991) 284-290
20. Haffmans J., Walsum M.V., van Amsterdam J.C., and Dzoljic M.R. Phelorphan, an inhibitor of enzymes involved in the biodegradation of enkephalins, affected the withdrawal symptoms in chronic morphine-dependent rats. Neuroscience 22 (1987) 233-236
21. Hao S., Mata M., Goins W., Glorioso J.C., and Fink D.J. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect. Pain 102 (2003) 135-142
22. Kayser V., Idanpaan-Hekkila J.J., Christensen D., and Guilbaud G. The selective cholecystokininB receptor antagonist L-365, 260 diminishes the expression of naloxone-induced morphine withdrawal symptoms in normal and neuropathic rats. Life Sci 62 (1998) 947-952
23. Kim S.H., and Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50 (1992) 355-363
24. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 (1997) 52-58
25. Ledeboer A., Liu T., Shumilla T.A., Mahoney J.H., Vijay S., Gross M.I., et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 2 (2007) 279-291
26. Livingston S.J., Sewell R.D., Rooney K.F., and Smith H.J. Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. Psychopharmacology (Berl) 94 (1988) 540-544
27. Maldonado R., Valverde O., Ducos B., Blommaert A.G., Fournie-Zaluski M.C., and Roques B.P. Inhibition of morphine withdrawal by the association of RB 101 an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308. Br J Pharmacol 114 (1995) 1031-1039
28. Marshall D.C., and Buccafusco J.J. Supraspinal and spinal mediation of naloxone-induced morphine withdrawal in rats. Brain Res 329 (1985) 131-142
29. Mata M., Glorioso J., and Fink D.J. Development of HSV-mediated gene transfer for the treatment of chronic pain. Exp Neurol 184 Suppl. 1 (2003) 25-29
30. Nitsche J.F., Schuller A.G., King M.A., Zengh M., Pasternak G.W., and Pintar J.E. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 22 (2002) 10906-10913
31. Rohde D.S., McKay W.R., Chang D.S., Abbadie C., and Basbaum A.I. The contribution of supraspinal, peripheral and intrinsic spinal circuits to the pattern and magnitude of Fos-like immunoreactivity in the lumbar spinal cord of the rat withdrawing from morphine. Neuroscience 80 (1997) 599-612
32. Shoblock J.R., and Maidment N.T. Enkephalin release promotes homeostatic increases in constitutively active mu opioid receptors during morphine withdrawal. Neuroscience 149 (2007) 642-649
33. Sribanditmongkol P., Sheu M.J., and Tejwani G.A. Inhibition of morphine tolerance and dependence by diazepam and its relation to the CNS Met-enkephalin levels. Brain Res 645 (1994) 1-12
34. Stevens C.W., and Yaksh T.L. Magnitude of opioid dependence after continuous intrathecal infusion of mu- and delta-selective opioids in the rat. Eur J Pharmacol 166 (1989) 467-472
35. Taylor D.A., and Fleming W.W. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J Pharmacol Exp Ther 297 (2001) 11-18
36. Trang T., Ma W., Chabot J.G., Quirion R., and Jhamandas K. Spinal modulation of calcitonin gene-related peptide by endocannabinoids in the development of opioid physical dependence. Pain 126 (2006) 256-271
37. Trang T., Sutak M., Quirion R., and Jhamandas K. The role of spinal neuropeptides and prostaglandins in opioid physical dependence. Br J Pharmacol 136 (2007) 37-48
38. Trang T., Sutak M., Quirion R., and Jhamandas K. Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal. Br J Pharmacol 140 (2003) 295-304
39. Trujillo K.A., Bronstein D.M., and Akil H. Regulation of opioid peptides by self-administered drugs. In: Hammer R.P. (Ed). Neurobiology of opioids (1993), CRC Press, Boca Raton, FL 223-256
40. Uhl G.R., Ryan J.P., and Schwartz J.P. Morphine alters preproenkephalin gene expression. Brain Res 459 (1988) 391-397
41. Valverde O., Maldonado R., Valjent E., Zimmer A.M., and Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 20 (2000) 9284-9289
42. Valverde O., Noble F., Beslot F., Dauge V., Fournie-Zaluski M.C., and Roques B.P. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 13 (2001) 1816-1824
43. Wen H.L. Clinical experience and mechanism of acupuncture and electrical stimulation (AES) in the treatment of drug abuse. Am J Chin Med 8 (1980) 349-353
44. Wen H.L. Clinical trial of met-enkephalin analogue (DAMME FK 33-824) on heroin abusers. Adv Biochem Psychopharmacol 33 (1982) 397-403
45. Wen H.L., and Ho W.K. Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur J Pharmacol 82 (1982) 183-186
46. Wen H.L., Ho W.K., and Wen P.Y. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur J Pharmacol 100 (1984) 155-162
47. Wilson S.P., Yeomans D.C., Bender M.A., Lu Y., Goins W.F., and Glorioso J.C. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 96 (1999) 3211-3216